Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study

References

• Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl). 2020;133(9):1015–1024.
   PubMed Web of Science ®Google Scholar
• Ma Z, Li P, Ikram A, et al. Does cross-neutralization of SARS-CoV-2 only relate to high pathogenic coronaviruses? Trends Immunol. 2020;41(10):851–853.
   Web of Science ®Google Scholar
• Zhou Z, Ren L, Zhang L, et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe. 2020;27(6):883–890.e2.
   PubMed Web of Science ®Google Scholar
• Guo L, Ren L, Yang S, et al. Profiling early humoral response to diagnose novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020;71(15):778–785.
   PubMed Web of Science ®Google Scholar
• Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–848.
   PubMed Web of Science ®Google Scholar
• Perera RA, Mok CK, Tsang OT, et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill. 2020;25(16):2000421.
   Google Scholar
• Gorse GJ, Patel GB, Vitale JN, et al. Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum. Clin Vaccine Immunol. 2010;17(12):1875–1880.
   PubMedGoogle Scholar
• Gao X, Zhou H, Wu C, et al. Antibody against nucleocapsid protein predicts susceptibility to human coronavirus infection. J Infect. 2015;71(5):599–602.
   Web of Science ®Google Scholar
• Monsalvo AC, Batalle JP, Lopez MF, et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med. 2011;17(2):195–199.
   Web of Science ®Google Scholar
• Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489–1501 e15.
   PubMed Web of Science ®Google Scholar
• Sagar M, Reifler K, Rossi M, et al. Recent endemic coronavirus infection is associated with less severe COVID-19. J Clin Invest. 2020;131(1):e143380.
   Web of Science ®Google Scholar
• Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020;26(7):1033–1036.
   PubMed Web of Science ®Google Scholar
• Zhou B, Liu J, Wang Q, et al. The nucleocapsid protein of severe acute respiratory syndrome coronavirus inhibits cell cytokinesis and proliferation by interacting with translation elongation factor 1alpha. J Virol. 2008;82(14):6962–6971.
   PubMed Web of Science ®Google Scholar
• Lv H, Wu NC, Tsang OT, et al. Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. Cell Rep. 2020;31(9):107725.
   PubMed Web of Science ®Google Scholar
• Chinese management guideline for Covid-19 (version 6.0). http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf.
   Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med. 2020;382(19):1787–1799.
   PubMed Web of Science ®Google Scholar
• Ren L, Fan G, Wu W, et al. Antibody responses and clinical outcomes in adults hospitalized with severe COVID-19: A post hoc analysis of LOTUS China trial. Clin Infect Dis. 2020. doi:https://doi.org/10.1093/cid/ciaa1247.
   Google Scholar
• National Health Commission of the People’s Republic of China. [Cited 2020 April 24]. http://www.nhc.gov.cn/.
   Google Scholar
• Guo L, Wang Y, Zhou H, et al. Differential seroprevalence of human bocavirus species 1-4 in Beijing, China. PLoS One. 2012;7(6):e39644.
   Web of Science ®Google Scholar
• Vijgen L, Keyaerts E, Moes E, et al. Development of one-step, real-time, quantitative reverse transcriptase PCR assays for absolute quantitation of human coronaviruses OC43 and 229E. J Clin Microbiol. 2005;43(11):5452–5456.
   Web of Science ®Google Scholar
• Matumoto M. A note on some points of calculation method of LD50 by Reed and Muench. Jpn J Exp Med. 1949;20(2):175–179.
   Google Scholar
• Sun B, Feng Y, Mo X, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):940–948.
   PubMed Web of Science ®Google Scholar
• Guo L, Zhang X, Ren L, et al. Human antibody responses to avian influenza A(H7N9) virus, 2013. Emerg Infect Dis. 2014;20(2):192–200.
   PubMed Web of Science ®Google Scholar
• Ng KW, Faulkner N, Cornish GH, et al. Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370(6522):1339–1343.
   PubMed Web of Science ®Google Scholar
• Kim D, Quinn J, Pinsky B, et al. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA. 2020;323(20):2085–2086.
   PubMed Web of Science ®Google Scholar
• Nowak MD, Sordillo EM, Gitman MR, et al. Coinfection in SARS-CoV-2 infected patients: where are influenza virus and rhinovirus/enterovirus? J Med Virol. 2020;92(10):1699–1700.
   PubMed Web of Science ®Google Scholar
• Ren L, Gonzalez R, Wang Z, et al. Prevalence of human respiratory viruses in adults with acute respiratory tract infections in Beijing, 2005–2007. Clin Microbiol Infect. 2009;15(12):1146–1153.
   Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.
   PubMed Web of Science ®Google Scholar
• Ding QLP, Fan Y, Xia Y, et al. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol. 2020;92(9):1549–1555.
   PubMed Web of Science ®Google Scholar
• Li Q, Guan X, Wu P, et al. Early transmission dynamics in wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–1207.
   PubMed Web of Science ®Google Scholar
• Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145(6):e20200702.
   PubMed Web of Science ®Google Scholar
• Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients Hospitalized with laboratory-confirmed coronavirus disease 2019 – COVID-NET, 14 states, March 1–30, 2020. MMWR Morb Mortal Wkly Re. 2020;69(15):458–464.
   PubMed Web of Science ®Google Scholar
• Chan CM, Tse H, Wong SS, et al. Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus. J Clin Virol. 2009;45(1):54–60.
   Web of Science ®Google Scholar
• Liu L, To KK-W, Chan K-H, et al. High neutralizing antibody titre in intensive care unit patients with COVID-19. Emerg Microbes Infect. 2020;9(1):1664–1670.
   PubMed Web of Science ®Google Scholar
• Katzelnick LC, Gresh L, Halloran ME, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358(6365):929–932.
   PubMed Web of Science ®Google Scholar
• Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019;4(4):e123158.
   PubMed Web of Science ®Google Scholar
• Yip MS, Leung HL, Li PH, et al. Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS. Hong Kong Med J. 2016;22(3 Suppl 4):25–31.
   PubMedGoogle Scholar
• Taylor A, Foo SS, Bruzzone R, et al. Fc receptors in antibody-dependent enhancement of viral infections. Immunol Rev. 2015;268(1):340–364.
   PubMed Web of Science ®Google Scholar